Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02287025 · ClinicalTrials.gov registry record · Phase 4
A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Outcomes?
A Phase 4 study, sponsored by Bayer.
- Terminated
- Registry status
- Phase 4
- Development phase
- 23
- Enrollment target
NCT02287025 is a Phase 4 study that was terminated before completion, run by Bayer. The registered enrollment target is 23 participants.
The verdict
NCT02287025, a Phase 4 study, was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 23 participants
- Enrollment target
Study Summary
Randomized trial to evaluate impact of healthcare provider( clinician and nursing staff) support and education on treatment discontinuation rates in the absence of progression in patients with metastatic colorectal cancer treated with regorafenib. Intensified education and support will be provided through an application for iPad which has automatic links to grading, dose reduction and side effect management ,as well as, references for additional articles.
Interventions
- DRUG Regorafenib (Stivarga, BAY73-4506)
- OTHER iPAD application
- OTHER Bayer specialist
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2014-11-11 |
| Est. Completion | 2016-04-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02287025
The ClinicalTrials.gov registry entry for NCT02287025 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Regorafenib (Stivarga, BAY73-4506) is the first listed.
NCT02287025 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02287025 about?
NCT02287025 is a clinical study titled "A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Outcomes?". Randomized trial to evaluate impact of healthcare provider( clinician and nursing staff) support and education on treatment discontinuation rates in the absence of progression in patients with metastatic colorectal cancer treated with regorafenib. Intensified education and support will be provided t...
What is the current status of trial NCT02287025?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 23 participants. The study started on 2014-11-11. Estimated completion is 2016-04-08.
What interventions are being tested in trial NCT02287025?
The interventions under investigation include: Regorafenib (Stivarga, BAY73-4506) (DRUG), iPAD application (OTHER), Bayer specialist (OTHER).
Who is sponsoring clinical trial NCT02287025?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.